共查询到20条相似文献,搜索用时 62 毫秒
1.
2.
动脉灌注化疗并同期放疗的综合治疗中晚期胰腺癌 总被引:4,自引:0,他引:4
目的观察动脉灌注化疗并同期放疗的综合治疗中晚期胰腺癌的作用。方法92年1月至96年1月收治52例中晚期胰腺癌,23例行动脉灌注化疗并同期放疗(综合组),29例行单纯放疗(单放组)。单放组每周照5次,每次180-200cGY,总量5000-6000cGY/5-6.7周,综合组动脉灌注化疗,每次5-Fu1.0、MMC10mg、DDP60mg,每4周一次,平均2.3次/人,同期放疗方案同单放组。结果腹痛、黄疸的症状缓解率两组之间无明显差异,但综合组黄疸改善时间较长(13个月对5个月P<0.05);肿瘤缩小率达50%以上综合组69.6%(16/23),单放组37.9%(11/29);两组1、2、3年生存率分别为78.5%、37.1%、26.7%和52.3%、22.9%、10.5%,综合组明显好于单放组。结论不能手术切除的中晚期胰腺癌通过动脉灌注化疗并同期放射治疗的综合治疗较单放组能获得较高的生存率。 相似文献
3.
4.
化放疗,放疗和化疗治疗肺癌脑转移的疗效评价 总被引:3,自引:0,他引:3
目的 评价化放疗,放疗和化疗治疗肺癌脑转移的疗效。方法 化疗加放疗32例,放疗19例,化疗11例,结果 化放疗组,放疗组和化疗组的中位生存期分别为6.9月,5.8月,3.6月;1年生存率分别为28.1%,21.1%,0%,经疗组的疗效虽稍优于放疗组,但在统计学上差异无显著性(P〉0.05)。而化疗疗组及放疗组明显好于化疗组(P〈0.05)。结论 化放疗及放疗特别是化放疗是治疗肺癌脑转移的有效治疗方 相似文献
5.
MNP与MVP方案治疗晚期非小细胞肺癌的疗效比较 总被引:1,自引:0,他引:1
目的:比较MNP方案(丝裂霉素、去甲长春碱、顺铂)与MVP方案(丝裂霉素、长春地辛、顺铂)治疗晚期非小细胞肺癌的疗效。方法:83例晚期非小细胞肺癌患者接受MNP与MVP方案化疗。病人一般特征经χ^2检验和t检验,两组具有可比性(P〉0.05)。MNP方案40例,MVP方案43例。结果:MNP组CR3例,PR15例,NC20例,PD2例,有效率为45.0%;中位缓解期8.0月,中位生存期10.5月,1年生存率42.5%。MPV组PR14例,NC20例,PD9例,有效率为32.6%;中位缓解期6.8月,中位生存期8.1月,1年生存率27.9%。两组有效率无显著性差异(P=0.06975,Radit分析),MNP组生存期优于MPV组,但无统计学差异(P=0.1516,Log-rank检验)。血液学毒性发生率MNP组高 相似文献
6.
多结节性肝癌的治疗探讨 总被引:1,自引:0,他引:1
总结292例多结节性肝癌的治疗。全身化疗111例,肝动脉栓塞化疗58例,多次局切67例,局切后并用肝动脉、门静脉插管化疗56例。结果:AFP转阴率分别为0、38.1%、74.5%、84.6%;各组1、2、3、5年生存率分别为18.2%、45.6%、52.2%、53.8%;1.9%、38.9%、25.8%、50.9%;0、7.5%、20.3%、46.3%;0、1.9%、5.2%、17.3%。提示,多结节性肝癌手术切除优于药物治疗,切除后并用肝动脉、门静脉插管化疗优于单纯局切,非手术治疗者。碘油抗癌药物乳化液栓塞治疗优于全身化疗(P均<0.05)。 相似文献
7.
CD3AK对晚期肝癌疗效初步观察 总被引:4,自引:0,他引:4
目的观察晚期肝细胞癌(HCC)患者采用抗CD3抗体激活的杀伤细胞(CD3AK)治疗的效果。方法58例晚期HCC患者分为三组,A组[CD3AK+肝动脉化学栓塞(TACE)]22例,B组(CD3AK)15例,C组(TACE)21例。结果部分缓解率(PR)A,B,C组分别为45.5%、13.3%(P<0.05)和14.3%(P<0.05),中位生存期分别为11.3月、4.9月(P<0.01)和4.1月(P<0.01),半年和1年生存率分别依次为68.2%,33.3%(P<0.05)和23.8%以及40.9%、6.6%(P<0.05)和9.5%(P<0.05)。结论本组结果表明CD3AK+TACE治疗晚期HCC疗效最佳 相似文献
8.
经皮经股动脉植入药盒治疗晚期原发性肝癌的临床疗效 总被引:9,自引:0,他引:9
目的探讨药盒在晚期原发性肝癌治疗中的临床价值。方法无外科手术及动脉栓塞指征的82例晚期原发性肝癌,依据动脉内化疗方式不同,分为两组:A组42例,采取经皮经股动脉植入药盒,术后经药盒1周或2周化疗1次;B组40例,采取每个月1次插管大剂量化疗。结果A、B两组有效率(CR+PR)分别为38.1%和15.0%(P<0.05)。A组6个月、1年、2年生存率分别为61.9%、28.6%、9.5%;B组分别为20%、5%、0%(P<0.01)。A组患者的生存质量明显改善,消化道反应、肝、胆、骨髓毒性均较B组低。结论经药盒间断性化疗并配合地塞米松治疗晚期原发性肝癌可明显改善患者的生存质量,提高生存率。 相似文献
9.
肿瘤介入治疗中动脉应用5-HT_3受体拮抗剂价值的探讨 总被引:1,自引:0,他引:1
目的:探讨恶性肿瘤介入治疗中动脉应用5-HT3受体拮抗剂对防治胃肠道副作用的价值。方法:采用随机对照研究,分为治疗组(n=120)和对照组(n=40),治疗组再分为欧必亭组(n=60)和非欧必亭组(n=60),其中 30例为自身对照。治疗组术中化疗/栓塞前 15分钟(n=60)或后即刻(n=60)于动脉内推注 5-HT3受体拮抗剂,对照组术中来用 5-HT3受体拮抗剂。主要采用 5-FU、DDP、MMC、THP或 ADM大剂量联合灌注化疗方案。结果:介入治疗术中急性胃肠道反应发生率为14.4%(23/160),其中治疗组为14.2%(17/120),对照组为15. 0%(6/40),两组差异无显著意义(P>0.05);但5-HT3受体拮抗剂介入化疗/栓塞前应用组明显优于化疗/栓塞后应用组(P<0.05)。出现胃肠道反应后立即停止操作,治疗组仍动脉内推注5-HT3受体拮抗剂。症状缓解率对照组为66.6%(4/6),治疗组达 100%;两组差异有显著意义(P<0,05)。术后 12小时、1天和3天胃肠道反应发生率对照组分别为47.5%(19/40)、45%(18/40)和37.5%(15/40),治疗组分别为1.6%(2 相似文献
10.
转移性肝癌外放射肝动脉化疗栓塞综合治疗 总被引:1,自引:0,他引:1
目的探讨转移性肝癌的外放射、肝动脉化辣栓塞的综合治疗价值。方法回顾性分析转移肝癌的肝动脉化疗栓塞、外放射综合治疗及单纯外放射治疗的治疗效果。综合治疗组的有效率为53.6%,1年、2年、3年生存率分别为60.7%、32.2%、14.3%、单纯放疗组的有效率为32%、1年、2年、3年经分别为44.0%、28.0%、12.0%。综合治疗组、单纯放疗组的平均生存期分别为14.6个月、11.8个月。其中Ⅲ期 相似文献
11.
12.
I. S. Morrison R. I. Thompson J. J. Glancy 《Journal of Medical Imaging and Radiation Oncology》1975,19(4):381-383
Venography is a particularly reliable method for the diagnosis of deep venous thrombosis but is not suitable as a screening test. Impedance phlebography represents another attempt to discover a simple, non-invasive and reliable method of detecting deep venous thrombosis. It does not, however, meet these criteria. 相似文献
13.
14.
《European journal of cancer (Oxford, England : 1990)》2014,50(7):1284-1290
PurposeTo evaluate prior compliance with guidelines in patients treated with salvage chemotherapy for advanced germ-cell tumours (GCT).Patients and methodsData concerning the initial management of patients requiring salvage chemotherapy for GCT at Institut Gustave Roussy between 2000 and 2010 were obtained and correlated with recommendations for treatment. Criteria of non-compliance were defined based on guidelines. Compliance with guidelines, predictive factors for non-compliance and the impact on outcome were analysed.ResultsAmong 82 patients treated in the salvage setting, guidelines to initial treatment were followed in only 41 cases (50%). The most common non-compliance criteria were non-adherence to the planned dose (16%), an inappropriate interval between first-line chemotherapy cycles (16%), the lack of post-chemotherapy surgery (16%) and a long interval to post-chemotherapy surgery (48%). Compliance with standard care was better in cancer centres than in other hospitals (private or public) (Odd Ratio (OR): 6.9, P = 0.001). A poor-risk status according to the International Germ Cell Cancer Collaborative Group (IGCCCG) was also predictive of compliance in univariate but not in multivariate analysis. No significant difference in outcome after salvage chemotherapy was observed. Patients relapsing after non-compliant first-line therapy tended to be more easily salvaged, which is consistent with the fact that their initial treatment was inadequate. Some of these relapses were therefore probably not due to true biologically refractory disease.ConclusionGuidelines for first-line treatment are adhered to in only half the patients requiring salvage chemotherapy. As the only predictive factor for non-compliance was the treating centre, centralisation of patients with GCT in well-trained hospitals should be recommended. 相似文献
15.
16.
《Annals of oncology》2016,27(11):2032-2038
BackgroundMethylnaltrexone (MNTX), a peripherally acting μ-opioid receptor (MOR) antagonist, is FDA-approved for treatment of opioid-induced constipation (OIC). Preclinical data suggest that MOR activation can play a role in cancer progression and can be a target for anticancer therapy.Patients and methodsPooled data from advanced end-stage cancer patients with OIC, despite laxatives, treated in two randomized (phase III and IV), placebo-controlled trials with MNTX were analyzed for overall survival (OS) in an unplanned post hoc analysis. MNTX or placebo was given subcutaneously during the double-blinded phase, which was followed by the open-label phase, allowing MNTX treatment irrespective of initial randomization.ResultsIn two randomized, controlled trials, 229 cancer patients were randomized to MNTX (117, 51%) or placebo (112, 49%). Distribution of patients' characteristics and major tumor types did not significantly differ between arms. Treatment with MNTX compared with placebo [76 days, 95% confidence interval (CI) 43–109 versus 56 days, 95% CI 43–69; P = 0.033] and response (laxation) to treatment compared with no response (118 days, 95% CI 59–177 versus 55 days, 95% CI 40–70; P < 0.001) had a longer median OS, despite 56 (50%) of 112 patients ultimately crossing over from placebo to MNTX. Multivariable analysis demonstrated that response to therapy [hazard ratio (HR) 0.47, 95% CI 0.29–0.76; P = 0.002) and albumin ≥3.5 (HR 0.46, 95% CI 0.30–0.69; P < 0.001) were independent prognostic factors for increased OS. Of interest, there was no difference in OS between MNTX and placebo in 134 patients with advanced illness other than cancer treated in these randomized studies (P = 0.88).ConclusionThis unplanned post hoc analysis of two randomized trials demonstrates that treatment with MNTX and, even more so, response to MNTX are associated with increased OS, which supports the preclinical hypothesis that MOR can play a role in cancer progression. Targeting MOR with MNTX warrants further investigation in cancer therapy.Clinical trials numberNCT00401362, NCT00672477. 相似文献
17.
Shimizu Ryutaro Honda Masashi Teraoka Shogo Yumioka Tetsuya Yamaguchi Noriya Kawamoto Bunya Iwamoto Hideto Morizane Shuichi Hikita Katsuya Takenaka Atsushi 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(1):175-183
International Journal of Clinical Oncology - Sarcopenia impacts perioperative outcomes and prognosis in various carcinomas. We aimed to investigate whether sarcopenia at the time of chemotherapy... 相似文献
18.
BACKGROUND:
Capecitabine, an oral alternative to 5‐fluorouracil (5‐FU) in patients with colorectal cancer (CRC), has equal clinical efficacy and a favorable safety profile; however, its use may be limited because of unit cost concerns. In this study, the authors measured the cost of chemotherapy‐related complications during treatment with capecitabine‐ and 5‐FU–based regimens.METHODS:
Patients with CRC who received at least 1 administration of capecitabine or 5‐FU during 2004 and 2005 were identified from the Thomson MarketScan research databases. Monthly frequency and cost for 23 complications were recorded. Logistic regression was used to predict complication probability. General linear models were used to predict monthly complication cost and total monthly expenditure.RESULTS:
In total, 4973 patients with CRC met the inclusion criteria for this analysis. Although the most frequently observed complications were the same between capecitabine and 5‐FU (nausea and vomiting, infection, anemia, neutropenia, diarrhea), each was observed with greater frequency in 5‐FU–based regimens. The mean predicted monthly complication cost was significantly higher (by 136%) with 5‐FU monotherapy than with capecitabine monotherapy (difference, $601; 95% confidence interval [95% CI], $469‐$737). In addition, the mean predicted monthly complication cost for 5‐FU+oxaliplatin was higher than the cost with capecitabine plus oxaliplatin (difference, $1165; 95% CI, $892‐$1595). When acquisition, administration, and complication costs were taken into consideration, there were no significant differences in the total cost between capecitabine regimens and 5‐FU regimens.CONCLUSIONS:
Capecitabine compared well with 5‐FU–based therapy in patients with CRC and was associated with lower complication rates and associated costs. Cancer 2009. © 2009 American Cancer Society. 相似文献19.
20.
JOHNSTON S.R.D. (2010) European Journal of Cancer Care 19 , 561–563 Living with secondary breast cancer: coping with an uncertain future with unmet needs 相似文献